[Clinical observations on the use of a new synthetic agent (3,3-diphenyl-N-(alpha-methylphenethyl)-propylamine, Segontin) in coronary insufficiency syndromes].
D001713:Biphenyl Compounds; D003324:Coronary Artery Disease; D003327:Coronary Disease; D011299:Prenylamine; D011437:Propylamines; D013565:Sympatholytics; D013577:Syndrome; D014665:Vasodilator Agents
D001713:Biphenyl Compounds; D011299:Prenylamine; D011437:Propylamines; D013565:Sympatholytics; D014665:Vasodilator Agents; C010574:biphenyl
CORONARY DISEASE; SYMPATHOLYTICS; VASODILATOR AGENTS